Last reviewed · How we verify

metformin or sulfonylurea — Competitive Intelligence Brief

metformin or sulfonylurea (metformin or sulfonylurea) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiabetic agents (biguanide and sulfonylurea). Area: Diabetes.

marketed Antidiabetic agents (biguanide and sulfonylurea) Metformin: AMP-activated protein kinase (AMPK) pathway; Sulfonylureas: ATP-sensitive potassium channel (KATP) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

metformin or sulfonylurea (metformin or sulfonylurea) — Dr. Milan Gupta. Metformin decreases hepatic glucose production and improves insulin sensitivity, while sulfonylureas stimulate pancreatic beta cells to increase insulin secretion.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
metformin or sulfonylurea TARGET metformin or sulfonylurea Dr. Milan Gupta marketed Antidiabetic agents (biguanide and sulfonylurea) Metformin: AMP-activated protein kinase (AMPK) pathway; Sulfonylureas: ATP-sensitive potassium channel (KATP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiabetic agents (biguanide and sulfonylurea) class)

  1. Dr. Milan Gupta · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metformin or sulfonylurea — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-or-sulfonylurea. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: